Back

Onco360 selected as national pharmacy partner for AstraZeneca’s Etcamah

Verifying
  • Onco360 became AstraZeneca’s national pharmacy partner for Etcamah in the United States.
  • Etcamah reduced progression or death risk by 56% in the SERENA-6 study.
  • The therapy is indicated for adults with ESR1-mutated, HR-positive, HER2-negative advanced breast cancer.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.